CD74 Antibody (BU45), Novus Biologicals™

CD74

Western Blot 0.5-1ug/ml, Flow Cytometry 0.5-1ug/million cells, Immunocytochemistry/Immunofluorescence 1-2ug/ml, Immunoprecipitation 0.5-1ug/500ug protein lysate, Immunohistochemistry-Frozen 0.5-1ug/ml

Monoclonal

Purified

RUO

Human

P044233

972

B lymphoblastoid cell line HFB1

Primary

Store at 4C.

BU45

Western Blot, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Immunohistochemistry (Frozen)

Unconjugated

Mouse

Immunology

PBS with 0.05% BSA. with 0.05% Sodium Azide

CD74 antigen, CD74 antigen (invariant polypeptide of major histocompatibility complex, classII antigen-associated), CD74 molecule, major histocompatibility complex, class II invariant chain, DHLAGgamma chain of class II antigens, HLA class II histocompatibility antigen gamma chain, HLADG, HLA-DR antigens-associated invariant chain, HLA-DR-gamma, Ia antigen-associated invariant chain, Ia-associated invariant chain, Ia-GAMMA, Ii, MHC HLA-DR gamma chain, p33

CD74

IgG1 κ

Protein A purified

Recognizes proteins of 33, 35 and 41kDa, which are identified as various isoforms of CD74. Its epitope is localized in the extracellular domain of CD74. CD74 is a type II transmembrane protein which binds to the peptide binding groove of newly synthesized MHC class II alpha/beta heterodimers and prevents their premature association with endogenous polypeptides. The CD74 molecule plays a critical role in the presentation of peptides, by the MHC class II antigens, to CD4 positive lymphocytes. CD74 is expressed on MHC class II positive cells including B cells, a subset of activated T cells, monocytes, and dendritic cells and by various types of carcinomas. CD74 is expressed primarily by antigen presenting cells, such as B-lymphocytes (from before the pre-B cell stage to before the plasma cell stage), macrophages, and monocytes, and many epithelial cells. Anti-CD74 stains predominantly germinal center lymphocytes and B-cell lymphomas, but rarely T-cell lymphomas. Anti-CD74 has been shown to be useful in differentiating atypical fibroxanthoma (-) from malignant fibrous histiocytoma (+).